Tadrous M - Search Results

1

Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology.

Cadarette SM, Maclure M, Delaney JAC, Whitaker HJ, Hayes KN, Wang SV, Tadrous M, Gagne JJ, Consiglio GP, Hallas J. Cadarette SM, et al. Among authors: tadrous m. Pharmacoepidemiol Drug Saf. 2021 Jun;30(6):671-684. doi: 10.1002/pds.5227. Epub 2021 Apr 1. Pharmacoepidemiol Drug Saf. 2021. PMID: 33715267 Free PMC article. Review.

2

Disease risk score as a confounder summary method: systematic review and recommendations.

Tadrous M, Gagne JJ, Stürmer T, Cadarette SM. Tadrous M, et al. Pharmacoepidemiol Drug Saf. 2013 Feb;22(2):122-9. doi: 10.1002/pds.3377. Epub 2012 Nov 21. Pharmacoepidemiol Drug Saf. 2013. PMID: 23172692 Free PMC article. Review.

3

Variation in the days supply field for osteoporosis medications in Ontario.

Burden AM, Huang A, Tadrous M, Cadarette SM. Burden AM, et al. Among authors: tadrous m. Arch Osteoporos. 2013;8:128. doi: 10.1007/s11657-013-0128-1. Epub 2013 Mar 9. Arch Osteoporos. 2013. PMID: 23475734

4

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis.

Tadrous M, Wong L, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM. Tadrous M, et al. Osteoporos Int. 2014 Apr;25(4):1225-35. doi: 10.1007/s00198-013-2576-2. Epub 2013 Nov 28. Osteoporos Int. 2014. PMID: 24287510

5

Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis-reply to Pazianas and Abrahamsen.

Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM. Tadrous M, et al. Osteoporos Int. 2014 Nov;25(11):2671-2. doi: 10.1007/s00198-014-2789-z. Epub 2014 Jul 18. Osteoporos Int. 2014. PMID: 25035138 No abstract available.

6

Comparison of orally administered bisphosphonate drugs in reducing the risk of hip fracture in older adults: a population-based cohort study.

Cadarette SM, Lévesque L, Mamdani M, Perreault S, Juurlink DN, Paterson JM, Carney G, Gunraj N, Hawker GA, Tadrous M, Wong L, Dormuth CR. Cadarette SM, et al. Among authors: tadrous m. CMAJ Open. 2013 Sep 13;1(3):E97-E105. doi: 10.9778/cmajo.20130036. eCollection 2013 Sep. CMAJ Open. 2013. PMID: 25077113 Free PMC article.

7

Uptake and characteristics of zoledronic acid and denosumab patients and physicians in Ontario, Canada: impact of drug formulary access.

Burden AM, Tadrous M, Calzavara A, Cadarette SM. Burden AM, et al. Among authors: tadrous m. Osteoporos Int. 2015 May;26(5):1525-33. doi: 10.1007/s00198-014-3023-8. Epub 2015 Jan 21. Osteoporos Int. 2015. PMID: 25603794

8

Patterns of use for brand-name versus generic oral bisphosphonate drugs in Ontario over a 13-year period: a descriptive study.

Fraser LA, Albaum JM, Tadrous M, Burden AM, Shariff SZ, Cadarette SM. Fraser LA, et al. Among authors: tadrous m. CMAJ Open. 2015 Jan 13;3(1):E91-6. doi: 10.9778/cmajo.2014-0090. eCollection 2015 Jan-Mar. CMAJ Open. 2015. PMID: 25844376 Free PMC article.

9

Performance of the disease risk score in a cohort study with policy-induced selection bias.

Tadrous M, Mamdani MM, Juurlink DN, Krahn MD, Lévesque LE, Cadarette SM. Tadrous M, et al. J Comp Eff Res. 2015 Nov;4(6):607-14. doi: 10.2217/cer.15.40. Epub 2015 Nov 3. J Comp Eff Res. 2015. PMID: 26529307 Free article.

10

Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials.

Amiche MA, Albaum JM, Tadrous M, Pechlivanoglou P, Lévesque LE, Adachi JD, Cadarette SM. Amiche MA, et al. Among authors: tadrous m. Osteoporos Int. 2016 May;27(5):1709-18. doi: 10.1007/s00198-015-3455-9. Epub 2015 Dec 22. Osteoporos Int. 2016. PMID: 26694595 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

263 results

Search Page